MktsMarkets

Entrada Therapeutics, Inc.
NASDAQ: TRDAKey statistics
TRDA News
Stories mentioning TRDA from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 875.00 | 1,299 | 1,614 | 1,950 | 20,558 | 37,398 | 19,570 | 94,694 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 33,054 | 33,957 | 38,361 | 37,877 | 32,074 | 33,406 | 31,257 | 32,035 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 43,178 | 43,507 | 48,665 | 48,799 | 42,348 | 43,265 | 41,228 | 41,271 |
| Operating Income (Loss) | (42,303) | (42,208) | (47,051) | (46,849) | (21,790) | (5,867) | (21,658) | 53,423 |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 2,624 | 3,136 | 3,571 | 3,924 | 4,441 | 5,128 | 5,766 | 4,366 |
| Pretax Income | ||||||||
| Tax Provision | 38.00 | 92.00 | 654.00 | 178.00 | 0.00 | (1,870) | (1,860) | 2,758 |
| Net Income (Loss) | (39,717) | (39,164) | (44,134) | (43,103) | (17,349) | 1,131 | (14,032) | 55,031 |
| Earnings Per Share (Basic) | (0.95) | (0.95) | (1.06) | (1.04) | (0.42) | 0.03 | (0.35) | 1.61 |
| Earnings Per Share (Diluted) | (0.95) | (0.95) | (1.06) | (1.04) | (0.42) | 0.03 | (0.35) | 1.55 |
| Weighted Average Shares Outstanding (Basic) | 41,836 | 41,371 | 41,463 | 41,339 | 41,074 | 37,306 | 40,630 | 34,181 |
| Weighted Average Shares Outstanding (Diluted) | 41,836 | 41,371 | 41,463 | 41,339 | 41,074 | 39,003 | 40,630 | 35,507 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About TRDA
Entrada Therapeutics, Inc. (NASDAQ: TRDA) is a stock listed on the Nasdaq Stock Market under the ticker symbol TRDA. It last traded at $5.09 (Nov 13, 2026, 9:30 AM ET), down 1.6% on the day. That gives Entrada Therapeutics a market capitalisation of $170.2M.
Over the past 52 weeks TRDA has traded between $4.11 and $16.45.
Revenue for the quarter ended Mar 31, 2026 was $875.0K; a net loss of $39.7M. Revenue was down 95.7% from $20.6M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $875.0K | -$39.7M | -4539.1% |
| Dec 31, 2025 | $1.3M | -$39.2M | -3014.9% |
| Sep 30, 2025 | $1.6M | -$44.1M | -2734.4% |
| Jun 30, 2025 | $2.0M | -$43.1M | -2210.4% |
From Entrada Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…